Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference12 articles.
1. PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions;Rallidis;Hell J Cardiol,2016
2. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017
3. Eligibility for PCSK9 treatment in 734 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy;Glueck;Lipids Health Dis,2016
4. Lipoprotein-associated phospholipase A2 (Lp-PLA2) bound on high density lipoprotein is associated with lower risk of cardiac death in stable coronary artery disease patients: a three year follow-up;Rallidis;J Am Coll Cardiol,2012
5. Characteristics and long-term prognosis of patients with premature ST-elevation myocardial infarction and “normal or near normal” coronary arteries;Rallidis;Am J Cardiol,2017
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Familial hypercholesterolaemia: New directions on the diagnosis and treatment of an old disease;Hellenic Journal of Cardiology;2020-11
2. PCSK9 inhibitors in clinical practice: Novel directions and new experiences;Hellenic Journal of Cardiology;2020-07
3. A practical algorithm for the management of patients with statin-associated muscle symptoms;Hellenic Journal of Cardiology;2020-03
4. Impact of the 2019 European Guidelines on Diabetes in Clinical Practice: Real and Simulated Analyses of Lipid Goals;Journal of Cardiovascular Development and Disease;2020-02-05
5. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients;Atherosclerosis;2020-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3